Stacey Wright
Family · Garden City, IDNPI 1497716476
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.1% of the total across 185 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 22.6% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in ID with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 185 payments — averaging $30.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$1K
- Otsuka America Pharmaceutical, Inc.$760
- Alkermes, Inc.$705
- Neurocrine Biosciences, Inc.$454
- AbbVie$448
- Teva Pharmaceuticals USA, Inc.$370
- plus $2K from 15 others
What the payments were for
- Food & beverage$5,47597%
- Education$1663%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 25 | $1,277 |
| Otsuka America Pharmaceutical, Inc. | 24 | $760 |
| Alkermes, Inc. | 28 | $705 |
| Neurocrine Biosciences, Inc. | 14 | $454 |
| AbbVie | 22 | $448 |
| Teva Pharmaceuticals USA, Inc. | 14 | $370 |
| E.r. Squibb & Sons, L.L.C. | 6 | $320 |
| Abiomed | 3 | $231 |
| Vanda Pharmaceuticals Inc. | 8 | $158 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $147 |
| Axsome Therapeutics, Inc. | 5 | $145 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $143 |
| Idorsia Pharmaceuticals US Inc | 2 | $113 |
| Eisai Inc. | 6 | $105 |
| Ironshore Pharmaceuticals Inc. | 4 | $87 |
| Lundbeck LLC | 5 | $84 |
| Indivior Inc. | 2 | $33 |
| Merz North America, Inc. | 1 | $19 |
| Merck | 1 | $18 |
| Tris Pharma Inc | 1 | $16 |
| Corium, LLC | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$891
- INVEGA SUSTENNA$819
- COBENFY$253
- INGREZZA$240
- ABILIFY ASIMTUFII$225
- ABILIFY MAINTENA$225
- Impella$162
- SPRAVATO$128
- VRAYLAR$119
- INVEGA TRINZA$118
- UZEDY$117
- REXULTI$111
How this compares
$5,641 in reported general payments places this provider in the 95th percentile of 809 family providers in Idaho.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aripiprazole | 82 | $10,795 |
| RexultiBrexpiprazole | 13 | $8,684 |
| VyvanseLisdexamfetamine Dimesylate | 22 | $7,558 |
| TrintellixVortioxetine Hydrobromide | 13 | $6,433 |
| Clozapine | 21 | $2,350 |
| Oxcarbazepine | 20 | $2,179 |
| Duloxetine Hcl | 13 | $2,172 |
| Divalproex Sodium | 12 | $2,151 |
| Vilazodone Hcl | 32 | $1,869 |
| Lurasidone Hcl | 26 | $1,727 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 18 | $1,127 |
| Buspirone Hcl | 31 | $1,004 |
| Bupropion XlBupropion Hcl | 65 | $991 |
| Quetiapine Fumarate | 40 | $809 |
| Divalproex Sodium ErDivalproex Sodium | 25 | $784 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse, Trintellix | $143 | $13,99135 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $760 | $8,68413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 809 family providers in Idaho.
Other family in Garden City
- Joycelyn ReilandGarden City$8K
- Bobbi BullockNampa$609K
- Michael ParkerMeridian$69K
- Jessica BraksiekBoise$41K
- Travis BlaserBoise$33K
- Alysha SchlackNampa$23K
- Jennifer WatsonCoeur D Alene$21K
- Amber MasseIdaho Falls$17K
- Brian KittelsonMeridian$16K
- Devon MoserBoise$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.